The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover

Seed, Mary; O'Connor, B.; Perombelon, Nicholas; O'Donnell, M.; Reaveley, D. A.; Knight, Brian L.

doi:10.1016/0021-9150(93)90102-z

Cited by 86 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Dietary and pharmacological attempts to reduce Lp(a) have been mainly unsuccessful. 7 Nicotinic acid, 8,9 estrogen, 10,11 and alcohol [12][13][14][15] are among the few factors that appear to lower Lp(a) levels. Lowered Lp(a) levels have also been observed during IGF-I administration.…”

mentioning

confidence: 99%

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

Paassilta

Kervinen

Linnaluoto

et al. 1998

ATVB

View full text Add to dashboard Cite

Abstract-Lipoprotein(a) [Lp(a)] is an important risk factor for cardiovascular disease. Alcohol is one of the few nongenetic factors that lower Lp(a) levels, but the metabolic mechanisms of this action are unknown. Alcohol inhibits the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis. Alcohol might also affect IGF-binding protein-1 (IGFBP-1), which is an acute inhibitor of IGF-I. We studied how alcohol withdrawal affects Lp(a) levels and the GH/IGF-I/IGFBP-1 axis. Male alcohol abusers (nϭ27; 20 to 64 years old) were monitored immediately after alcohol withdrawal for 4 days. Twenty-six healthy men, mainly moderate drinkers, served as control subjects. Fasting blood samples were drawn to determine Lp(a), IGF-I, and IGFBP-1 (by ELISA, RIA, and immunoenzymometric assay, respectively). Nocturnal (12 hours) urine collection was performed in 9 alcoholics and 11 control subjects for GH analyses (RIA). The groups were similar in age and body mass index. Lp(a), GH, and IGF-I tended to be lower and IGFBP-1 higher in the alcoholics immediately after alcohol withdrawal than in the control subjects. During the 4-day observation in alcoholics, Lp(a) levels increased by 64% and IGF-I levels by 41%, whereas IGFBP-1 levels decreased by 59% (PϽ.001 after ANOVA for all comparisons). Urinary GH levels tended to decline. The increase in Lp(a) correlated inversely with the changes in IGFBP-1 (rϭϪ.63, PϽ.001, nϭ27) and GH (rϭϪ.70, PϽ.05, nϭ9), but not with IGF-I. In multiple regression analysis, the main predictors for the increase in Lp(a) were IGFBP-1 and urinary GH.

show abstract

mentioning

confidence: 99%

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

Paassilta

Kervinen

Linnaluoto

et al. 1998

ATVB

View full text Add to dashboard Cite

show abstract

“…For example, nicotinic acid produces a 20% to 40% lowering of Lp(a), but also reduces LDLC and triglycerides and raises HDLC. 48 The mechanism seems to be a reduction in Lp(a) synthesis, without an effect on catabolism or clearance, so it is likely to be independent of SR-B1. 49 Inhibitors of PCSK9 (proprotein convertase subtilisin/kexin type 9) lower Lp(a) by 20% to 30% in addition to their primary effect on LDLC.…”

Section: Discussionmentioning

confidence: 99%

SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a)

Yang

Sethi

Yanek

et al. 2016

Circ Cardiovasc Genet

View full text Add to dashboard Cite

show abstract

“…Other drug therapies that have produced a significant reduction in Lp(a) concentration include niacin alone or in combination with a bile acid sequestrant or neomycin (9,10,40). Niacin reduces Lp(a) levels without affecting the fractional catabolic rate of the lipoprotein, suggesting that treatment with this drug decreases the rate of Lp(a) synthesis and not its removal from plasma (41). In the traditional form, niacin at 4 g/day decreased the plasma Lp(a) concentrations by 38% in hypercholesterolemic patients (9).…”

Section: Discussionmentioning

confidence: 99%

Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects

Spósito

Mansur

Maranhão

et al. 2001

Braz J Med Biol Res

View full text Add to dashboard Cite

Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hydrolases, both constituents are gradually released in a controlled-release manner. In this study, we compared the effects of etofibrate and controlled-release niacin on lipid profile and plasma lipoprotein (a) (Lp(a)) levels of patients with triglyceride levels of 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl. These patients were randomly assigned to a double-blind 16-week treatment period with etofibrate (500 mg twice daily, N = 14) or niacin (500 mg twice daily, N = 11). In both treatment groups total cholesterol, VLDL cholesterol and triglycerides were equally reduced and high-density lipoprotein cholesterol was increased. Etofibrate, but not niacin, reduced Lp(a) by 26% and lowdensity lipoprotein (LDL) cholesterol by 23%. The hybrid compound etofibrate produced a more effective reduction in plasma LDL cholesterol and Lp(a) levels than controlled-release niacin in type IIb dyslipidemic subjects.

show abstract

The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover

Cited by 86 publications

References 23 publications

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a)

Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects

Contact Info

Product

Resources

About